Crinetics Pharmaceuticals is an SST2-pathway-focused company building a peptide-and-non-peptide pipeline against neuroendocrine and endocrine targets that historically have relied on injectable somatostatin analogs.
The lead asset Palsonify (paltusotine) is the first once-daily oral SST2 nonpeptide agonist for acromegaly — the European Commission approved it on April 27, 2026 across the 27 EU member states plus Iceland, Liechtenstein, and Norway, with first launches planned in Germany and Austria. The May 7 Q1 print disclosed Palsonify net product revenue of $10.3M in its first full commercial quarter (nearly doubling from $5.4M in Q4 2025), with 263 unique prescribers (up from 125 at year-end), 232 new patient enrollment forms in the quarter, and approximately 70% reimbursement with payer coverage above 60%. R&D rose 17.6% to $100.1M to fund Phase 3 paltusotine in carcinoid syndrome plus atumelnant Phase 3 programs in congenital adrenal hyperplasia and Cushing's syndrome. CRN09682, a first-in-class SSTR2 non-peptide drug conjugate coupling a small-molecule SST2 agonist with monomethyl auristatin E via a cleavable linker, is in the Phase 1/2 BRAVESST2 trial in metastatic neuroendocrine tumors and other SST2-expressing solid tumors — directly competing with peptide radioconjugates including Lutathera and Perspective Therapeutics' alpha-PRRT.
Stories here cover trial readouts, regulatory milestones, and the broader SST2 competitive landscape. See #palsonify, #crn09682, and #sstr2.
Crinetics Pharmaceuticals reported Q1 2026 results May 7 — total revenue $10.7M (vs $8.5M consensus, +25.7% beat), Palsonify (paltusotine) net product revenue $10.3M in its first full commercial quarter (up from $5.4M in Q4 2025), 263 unique prescribers (up from 125 at year-end), 232 new patient enrollment forms in the quarter, and approximately 70% of patients reimbursed with payer coverage above 60% (target above 75% by Q3). Cash, equivalents, and investments closed at $1.3B. R&D rose 17.6% to $100.1M to fund Phase 3 paltusotine in carcinoid syndrome plus atumelnant Phase 3 programs in congenital adrenal hyperplasia and Cushing's syndrome. Shares rose 4.3% in after-hours trading.
Crinetics Pharmaceuticals reports Q1 2026 financial results after market close May 7, with a 4:30 p.m. ET conference call. Investors will be looking for first commercial color on Palsonify (paltusotine), the once-daily oral SST2 nonpeptide agonist that won European Commission approval April 27 for adult acromegaly across the 27 EU member states plus three EEA countries (Iceland, Liechtenstein, Norway). First launches are planned for Germany and Austria. Q1 commentary on CRN09682 — the first-in-class SSTR2 non-peptide drug conjugate currently in Phase 1/2 BRAVESST2 in metastatic neuroendocrine tumors — is also expected, with the program designed as a direct challenge to peptide-based PRRT including Lutathera and Perspective Therapeutics' alpha-PRRT.
Crinetics Pharmaceuticals announced April 27 that the European Commission approved Palsonify (paltusotine), a selectively-targeted somatostatin receptor type 2 nonpeptide agonist, as the first once-daily oral therapy for acromegaly in adults across all 27 EU member states plus three EEA countries. The approval rests on two pivotal Phase 3 trials in medical-naïve and previously treated patients, with diarrhea, abdominal pain, and nausea reported as the most common adverse reactions and no serious adverse events in the randomized portion. First launches are planned for Germany and Austria, marking Crinetics' first regulatory approval outside the U.S. and a competitive challenge to injectable somatostatin analogs.
BioWorld reported April 24 on Crinetics Pharmaceuticals' CRN09682, a first-in-class non-peptide drug conjugate (NDC) coupling a small-molecule somatostatin receptor 2 (SST2) agonist to monomethyl auristatin E (MMAE) via a cleavable linker. The compound is in Phase 1/2 BRAVESST2 trial in metastatic neuroendocrine tumors and other SST2-expressing solid tumors — directly competing with peptide-radioconjugate therapies like Novartis' Lutathera and Perspective Therapeutics' alpha-PRRT. The non-peptide approach trades off receptor-binding peptide selectivity for small-molecule manufacturing simplicity.